January 2, 2026

How daignostics will be monetised at scale Six monetisation models are emerging for autonomous AI diagnostics at scale. Capital is flowing, unit economics work, and billions need access now. Table of contents The economic foundation Model one: dual-tier care Model two: institutional licensing and SaaS Model three: direct-to-consumer Model four: employer-sponsored access Model five: philanthropic seeding with commercial transition Model six: data as payment The subsidy effect Resilience across economic cycles Capital market validation Deployment strategy The structural case 1. The economic foundation The commercial logic behind daignostics is no longer theoretical. Telehealth adoption, digital health expenditure, and investment patterns have already demonstrated the viability of remote diagnostic delivery. The remaining task is execution at scale – serving populations that traditional healthcare economics cannot reach. Europe illustrates the trajectory. The region's digital health market is valued at roughly $96.7 billion in 2025 and is forecast to exceed $220 billion by 2030.((Mordor Intelligence (2025), European Digital Health Market Forecast 2025-2030.)) Venture funding remains strong: $3.4 billion was raised across 182 European deals in the first half of 2025, representing more than a quarter of global digital health investment.((Galen Growth (2025), European Digital Health Bucks the Trend: H1 2025 Funding.)) Global telemedicine markets continue to grow at double-digit rates, with Europe's telemedicine sector reaching $37.7 billion in 2024 and projected to hit $46.5 billion in 2025, growing at 23.6% annually through 2033.((Market Data Forecast (2025), European Telemedicine Market Analysis 2024-2033.)) Market size alone, however, is meaningless without workable monetisation. Six viable models are emerging. They differ by regulatory environment, economic maturity, and speed of adoption. In practice, successful daignostic platforms will deploy several models concurrently rather than rely The aim is not to replace clinicians but to reallocate their time. A specialist reviewing routine ECGs is an inefficient use of resources when daignostic systems can detect anomalies in milliseconds. 2. Model one: dual-tier care This model separates high-complexity and low-complexity care. Human-led diagnostics retain premium status for complex or high-risk cases. Daignostic systems – autonomous AI diagnostic platforms operating independently of direct human oversight – cover routine consultations at scale and at marginal cost. The aim is not to replace clinicians but to reallocate their time. A specialist reviewing routine ECGs is an inefficient use of resources when daignostic systems can detect anomalies in milliseconds. Human time is then focused on interventions where judgement cannot be automated. Economically, premium human diagnostics continue at current market rates while AI-led consultations generate volume-based revenue. Some 44 European countries now have national digital health strategies.((World Health Organization Regional Office for Europe (2024), Digital Health in the WHO European Region. https://www.who.int/europe/publications/digital-health-in-the-who-european-region-the-ongoing-journey-to-commitment-and-transformation)) Hybrid models have already delivered 15 to 25% reductions in routine consultation costs when AI and telehealth handle triage and follow-up.((JMIR mHealth and uHealth (2023), Hybrid Care Models: Cost Reduction Analysis. https://mhealth.jmir.org)) Germany's DiGA (Digital Health Applications) framework shows that regulated digital health tools can generate substantial reimbursable income – 64 approved applications generated over €234 million in cumulative reimbursable revenue since inception.`((MTR Consult / GKV-Spitzenverband (2024), DiGA Directory and Revenue Analysis. https://mtrconsult.com/news/gkv-report-utilization-and-development-digital-health-application-diga-care-germany)) The primary risk is commoditisation. As daignostic accuracy improves, the premium for human oversight may narrow. Providers will need formal rules that reserve complex cases for human review to maintain differentiation. 3. Model two: institutional licensing and SaaS Licensing daignostic systems to insurers, hospitals, and government providers offers stable recurring revenue and aligns incentives with large purchasers. The demand is already visible. Europe faces a projected shortage of 1.8 million clinicians by 2030,((Health Policy Watch (2023), European Health Workforce Projections: Europe Struggles to Keep Health Systems Afloat.)) while chronic diseases absorb more than 70% of regional health spending.((European Commission (2022), Health at a Glance: Europe 2022.)) Systems under pressure need cost-effective triage, monitoring, and decision support. Cloud-based platforms dominate Europe's digital health market, capturing 57.6% of the sector in 2024 as providers embrace elastic compute and rapid feature deployment.((Mordor Intelligence (2024), Cloud-Based Digital Health Platform Adoption in Europe.)) Once deployed, routine daignostic costs fall below €5 per patient.((ICTHealth.org (2024), Cloud-Based Telehealth Cost Structures.)) At modest scale – for example, 100,000 consultations monthly at €10 per consultation – revenue becomes predictable at €500,000 monthly (€6 million annually), with margins remaining attractive even after infrastructure and compliance costs. Horizon Europe has earmarked €13 billion for digital activities between 2025-2027, with €67.5 million specifically allocated for AI-assisted healthcare.((European Commission (2024), Horizon Europe Digital Activities Budget 2025-2027.)) Public funding de-risks commercial deployment and validates business models at the policy level. The obstacle is reimbursement. Approval processes differ by jurisdiction. What succeeds in Germany may fail outright in France or Poland. Payers resist new spending unless it clearly replaces existing costs. Evidence takes years to generate, yet evidence requires scale, and scale often requires reimbursement. Three tactics mitigate this friction. Hybrid payment approaches allow payers to test limited daignostic integration before committing to wholesale adoption. Structured pilots prove savings in targeted patient cohorts – chronic disease monitoring, post-surgical follow-up – where measurable reductions in emergency department visits, hospitalisations, and specialist consultations can be demonstrated. Early engagement with regulators during product development helps shape approval pathways rather than adapting to them retrospectively. Germany's DiGA pathway succeeded precisely because developers participated in designing the approval criteria alongside regulators. Institutional reimbursement is necessary for certain markets but too slow and fragmented to serve as the only strategy. 4. Model three: direct-to-consumer Where institutional barriers are high, direct-to-consumer deployment bypasses them entirely. India demonstrates the opportunity: over 700 million smartphone users, massive unmet healthcare need, and underdeveloped insurance infrastructure. Direct-to-consumer health applications have achieved substantial scale without navigating reimbursement bureaucracies. In India, consumers already pay small fees – ₹50-200 per consultation ($0.60–$2.40) – because the alternatives are travelling hours to overcrowded clinics or going untreated. Low-cost daignostic systems deployed through familiar platforms such as WhatsApp, combined with mobile money payments and local pharmacy fulfilment, demonstrate how a complete value chain can operate outside traditional infrastructure. This model is also attractive across Sub-Saharan Africa, where mobile money penetration exceeds formal banking infrastructure and trust in state healthcare systems is inconsistent. Revenue depends on very low marginal cost and high volume, with social virality replacing traditional marketing spend. Challenges include payment fraud, regulatory unpredictability, quality assurance without institutional oversight, and managing user expectations when daignostics cannot address emergency conditions. Despite these constraints, for large segments of the global population this represents the only accessible route to basic diagnostics. 5. Model four: employer-sponsored access Corporate buyers in emerging markets represent a distinct and underappreciated opportunity. Employers absorb the cost of absenteeism and have strong incentives to maintain workforce health. Daignostic subscriptions priced at $2-5 per employee monthly can reduce productivity losses by far greater amounts. A garment factory in Bangladesh with 5,000 workers loses revenue every day employees miss work for preventable health issues. Providing free daignostic access for chronic disease monitoring, basic triage, and preventive care delivers measurable return on investment through reduced absenteeism and improved employee satisfaction. Many employers in India, Southeast Asia, and Latin America already provide various health benefits. Replacing on-site clinic models with remote daignostic access offers predictable cost savings whilst maintaining or improving healthcare access. Remote workers, distributed teams, and gig economy platforms particularly benefit from location-agnostic healthcare delivery. Sales cycles are more straightforward than with public payers. Demonstrate cost savings per employee, pilot with a willing cohort, then scale based on measurable outcomes. Revenue takes the form of durable B2B subscription contracts – less volatile than consumer payments or reimbursement negotiations. 6. Model five: philanthropic seeding with commercial transition This model uses philanthropic funding to overcome early market barriers. Gates Foundation, WHO, Wellcome Trust, and similar organisations subsidise initial algorithm development, regulatory approval, clinical validation studies, and first-stage deployment in underserved regions. Once clinical efficacy and economic viability are established, commercial capital funds geographic scaling. The pattern is well established in global health: vaccine development, malaria interventions, and HIV treatment programmes all followed similar trajectories. Philanthropy breaks the cold-start problem where commercial investors demand proof but proof requires initial deployment. Commercial investment then supports long-term sustainability. Governance structures must prevent mission drift as ventures transition from philanthropic to commercial funding. Philanthropic funders prioritise impact over profit whilst commercial investors demand returns. Balancing these objectives requires careful milestone-based transitions between funding phases. Executed well, however, this model accelerates time-to-market in the world's most underserved populations. 7. Model six: data as payment A growing model provides free or heavily subsidised daignostics in exchange for fully anonymised health data. This data holds commercial value for pharmaceutical research, real-world evidence generation, and epidemiological modelling. The economics are clear. High-diversity, population-level diagnostic datasets from billions of people across varied geographies and genetic backgrounds are scarce and lucrative. Pharmaceutical companies pay substantial sums for real-world evidence on treatment efficacy. Epidemiologists require population health data. AI researchers need diverse training datasets to improve algorithm performance. Users receive free daignostics. Platforms monetise anonymised data through research partnerships, data licensing, and algorithm improvement services. Properly structured with robust privacy protections, this creates sustainable revenue without requiring user payment or reimbursement approval. Crucially, this model also creates a feedback loop that strengthens the daignostic sector itself: wider usage generates better datasets, which produce more accurate algorithms, which increase clinical credibility and further adoption. Unlike AI-assisted diagnostics, where algorithms support human decision-making, daignostic systems operate autonomously – making continuous algorithmic improvement through population-scale data particularly valuable. Ethical and regulatory challenges are substantial, and this model may face the strongest public resistance despite its economic logic. Data privacy laws vary dramatically across jurisdictions. GDPR in Europe imposes severe penalties for violations. User consent must be informed and revocable. Anonymisation must be genuine and irreversible. The perception of "exploiting poor people's data" requires careful management. Nonetheless, the economic logic mirrors that of consumer internet platforms, which have operated on data-for-service models for decades. Healthcare data is more sensitive and requires stronger protections, but the fundamental commercial structure holds. The question is execution – building sufficient trust and safeguards to make the model socially acceptable. 8. The subsidy effect Across all models, a counter-intuitive principle emerges: high-volume, low-cost daignostic services become the profit engine that funds premium care, specialist algorithms, and regulatory compliance – inverting traditional healthcare's subsidy structure. Traditional healthcare relies on premium services to cross-subsidise basic care. Daignostics inverts this structure and becomes cost-positive at scale. The mathematics are compelling. Revenue from 100,000 routine daignostic consultations at €10 each generates €1 million monthly. This can fund specialised diagnostic algorithm development, clinical validation studies, or integration with complex care pathways – activities that would be financially prohibitive if the entire cost base had to be carried by premium services alone. AI diagnostics reportedly reduce operational costs by 20-30% per patient for routine monitoring.((McKinsey & Company (2024), Tackling Healthcare's Biggest Burdens with Generative AI.)) These savings compound as volume scales. The European Health Data Space initiative, which mandates standardised electronic health records from March 2025, provides regulatory infrastructure for integrated daignostic deployment across member states.((European Commission (2025), European Health Data Space Implementation Timeline.)) Broad adoption remains the requirement, and uptake varies by region, digital literacy, and infrastructure readiness. The strategy focuses initial rollouts in digitally mature markets or high-need environments with minimal regulatory friction. These deployments validate the model before expansion into structurally challenging markets. 9. Resilience across economic cycles Digital health investments have remained resilient despite recent economic volatility. Telemedicine and digital monitoring reduced hospital admissions during the pandemic and demonstrated value precisely when healthcare systems faced maximum strain. Data from 2020-2025 indicates that digital health investments maintained or increased activity during economic downturns.((Galen Growth (2025), Digital Health Investment Patterns 2020-2025.)) While global digital health investment is expected to close 2025 at $25-26 billion – below historic peaks – this represents a sustainable baseline for future expansion.((Galen Growth (2025), Global Digital Health Investment Outlook 2025.)) European funding has declined less sharply than other regions. Global investment fell 23% quarter-on-quarter in Q3 2025, but European funding declined only 17%, demonstrating relative resilience.((Galen Growth (2025), Regional Digital Health Funding Comparison Q3 2025.)) The counter-cyclical logic is straightforward. In downturns, health systems seek efficiency without service degradation. Daignostics deliver both. Public payers facing austerity favour proven cost-saving technologies. Private patients may defer elective procedures but still require chronic disease monitoring – a core daignostic use case. Severe budget cuts may still delay funding regardless of return on investment. Capital constraints can override rational cost-benefit analysis. Revenue diversification across public reimbursement, private insurance, employer contracts, direct consumer payment, and philanthropic support protects against disruptions in any single funding stream. 10. Capital market validation Investor behaviour confirms sector maturity. Europe experienced $2.0 billion in Q1 2025 funding (excluding exits), an 82% year-on-year increase driven by private capital rather than public subsidies.((Galen Growth (2025), European Digital Health Funding Q1 2025.)) Average deal size reached $27.0 million, up 85% year-on-year, with mega-deals exceeding $100 million dominating the landscape.((Galen Growth (2025), European Health-Tech Deal Sizes 2025.)) In Q3 2025, AI-enabled ventures dominated funding flows, especially in oncology and preventive health. Examples include CHARM Therapeutics ($80 million) and MRM Health ($64.5 million).((CHARM Therapeutics (2025), Major AI Healthcare Funding Rounds Q3 2025.)) These funding rounds validate that AI-powered healthcare is no longer experimental – it is infrastructure. Investors deploy capital selectively, showing strong preference for ventures that convert clinical validation into tangible revenue. Growth capital increasingly backs proven daignostic platforms ready for scale rather than speculative early-stage projects. The "spray and pray" approach to digital health investment is dead. Capital now demands clear outcomes: validated clinical efficacy, proven cost savings, and scalable unit economics. European health-tech firms with validated cost savings achieve 5.5-7× revenue multiples, with EBITDA multiples around 10-14×.((Mordor Intelligence (2025), European Health-Tech Valuation Multiples.)) Growth stage investments (Series B and C) represented 67% of Q3 2025 European digital health funding, demonstrating capital markets' clear preference for scaling proven solutions over speculative early-stage ventures.((Galen Growth (2025), European Digital Health Funding Analysis Q3 2025: Investment Stage Breakdown.)) This selectivity benefits credible daignostic platforms. The bar is higher, but clearing it attracts substantial capital at attractive valuations. Companies demonstrating real-world cost reduction and positive health outcomes can access growth capital at scale. The market is not waiting for validation. It is already forming. Multiple billion-dollar markets are emerging, capital is flowing to credible platforms, and the unit economics are inexorable. 11. Deployment strategy A practical framework is emerging. Phase one (12-18 months): Validate in high-need, low-barrier markets through direct-to-consumer and employer-sponsored models. Deploy in India, Southeast Asia, and Sub-Saharan Africa. Generate real-world evidence on clinical efficacy and cost savings. Build user base and refine algorithms with diverse patient populations. Phase two (18-24 months): Use early evidence to pursue institutional partnerships in mature markets. Leverage validation data to secure pilot programmes with European health systems, negotiate reimbursement frameworks, and establish regulatory approvals. Use these credentials to approach other developed-market payers. Phase three (24-36 months): Deploy region-specific hybrids combining consumer access, institutional licensing, corporate contracts, and philanthropic initiatives. Optimise revenue mix based on geographic constraints and regulatory frameworks. Combine institutional licensing in markets with established reimbursement, direct-to-consumer in markets without, and employer-sponsored models for workforce health. Phase four (36+ months): Introduce data monetisation with strict privacy protections once sufficient scale is achieved. Use this additional revenue stream to subsidise free access for lowest-income users, creating a virtuous cycle where commercial success funds humanitarian impact. The critical insight: no single model will dominate. The opportunity lies in deploying multiple approaches simultaneously, adapted to local market conditions. Winners will be operationally sophisticated enough to manage diverse revenue streams across regulatory jurisdictions whilst maintaining consistent daignostic quality and accuracy. 12. The structural case The enabling conditions for daignostic scale are already in place. Proven business models exist across adjacent telehealth markets. Abundant private capital is available – evidenced by 2025 funding flows – alongside public funding mechanisms such as Horizon Europe. Demographic pressure is inexorable: ageing populations, rising chronic disease burden, and projected clinician shortages create sustained demand that traditional models cannot meet cost-effectively. Unit economics enable profitability at price points traditional healthcare delivery cannot match, making previously uneconomic populations commercially viable for the first time. The market is not waiting for validation. It is already forming. Multiple billion-dollar markets are emerging, capital is flowing to credible platforms, and the unit economics are inexorable. The question isn't whether daignostics will scale. The question is which specific platforms execute most effectively – which achieve clinical validation, navigate regulatory approval, secure diverse revenue streams, and scale operations before competitors. The remaining question is execution. The first platforms to combine clinical accuracy, regulatory approval, economic discipline, and operational scale will define the daignostic sector. For billions with no realistic access to traditional healthcare, daignostics represent the only financially viable model available. The reimbursement battles will be prolonged. Institutional resistance will be fierce. Regulatory complexity will be maddening. But the economics of daignostic delivery are inexorable. When marginal cost approaches zero and addressable markets span billions, autonomous AI diagnostics cease being experimental and become essential infrastructure. The terminology shift from "AI-assisted" to "daignostic" reflects this fundamental transition – from augmentation to autonomy, from premium to universal, from supplement to system.

January 2, 2026

Monetising daignostics